Related Experiment Video
Updated: Jun 9, 2026
Stem Cell-Derived Viral Ag-Specific T Lymphocytes Suppress HBV Replication in Mice
Published on: September 25, 2019
Growth suppression of human laryngeal squamous cell carcinoma by adenoviral-mediated interleukin-12
1Department of Otorhinolaryngology/Head and Neck Surgery, The Second Affiliated Hospital of Harbin Medical University, Harbin, China.
Abstract:
This study explored the inhibitory role of the adenoviral-mediated-interleukin (IL)-12 (Ad.mIL-12) gene in the growth of laryngeal squamous cell carcinoma (LSCC). Human epithelial type 2 (Hep-2) cells were transfected with Ad.mIL-12, and IL-12 gene expression of the cells was evaluated. The proliferation and apoptosis of Hep-2 cells in vitro were detected by MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) assay and flow cytometry. Experimental tumours in mice were injected intratumourally with the same recombinant adenoviruses and inhibition of tumour growth observed. Apoptosis in Hep-2 xenotransplants was detected using TUNEL (terminal deoxynucleotidyl transferase dUTP nick-end labelling) assay and transmission electron microscopy. The expression of IL-12 in Ad.mIL-12 transfected Hep-2 cells was significantly increased. In vitro, Ad.mIL-12 decreased the viability of and increased apoptosis in Hep-2 cells. Increased apoptosis was also seen in vivo. The mean weight and volume of tumours in Ad.mIL-12 treated mice were significantly lower than in the control group. It is concluded that Ad.mIL-12 can suppress LSCC growth and induce apoptosis.
Insights
Adenoviral-mediated interleukin-12 (Ad.mIL-12) gene therapy effectively suppressed laryngeal squamous cell carcinoma (LSCC) growth. This gene therapy promoted cancer cell apoptosis both in vitro and in vivo, offering a potential new treatment strategy for LSCC.
Area of Science:
- Oncology
- Gene Therapy
- Molecular Biology
Background:
- Laryngeal squamous cell carcinoma (LSCC) is a significant cause of cancer-related mortality.
- Current treatments for LSCC have limitations, necessitating novel therapeutic approaches.
- Interleukin-12 (IL-12) is a cytokine with known immunomodulatory and anti-tumor properties.
Purpose of the Study:
- To investigate the inhibitory effect of adenoviral-mediated interleukin-12 (Ad.mIL-12) gene on LSCC growth.
- To evaluate the impact of Ad.mIL-12 on LSCC cell proliferation and apoptosis in vitro and in vivo.
- To assess the therapeutic potential of Ad.mIL-12 gene therapy for LSCC.
Main Methods:
- Human epithelial type 2 (Hep-2) cells were transfected with Ad.mIL-12 to assess IL-12 gene expression.
- In vitro proliferation and apoptosis were measured using MTT assay and flow cytometry.
- In vivo tumor growth inhibition was evaluated in mice bearing experimental tumors, with apoptosis assessed via TUNEL assay and transmission electron microscopy.
Main Results:
- Ad.mIL-12 transfection significantly increased IL-12 gene expression in Hep-2 cells.
- In vitro studies demonstrated that Ad.mIL-12 reduced Hep-2 cell viability and induced apoptosis.
- In vivo experiments showed significant tumor growth inhibition, reduced tumor weight and volume, and increased apoptosis in Ad.mIL-12 treated mice compared to controls.
Conclusions:
- Ad.mIL-12 gene therapy demonstrates a potent ability to suppress LSCC growth.
- Ad.mIL-12 effectively induces apoptosis in LSCC cells, both in vitro and in vivo.
- This study supports Ad.mIL-12 as a promising therapeutic agent for laryngeal squamous cell carcinoma.
